Chinese contract development organisation PharmaLegacy has received approximately $100 million in a fresh round of financing.
The new round was co-led by return investors namely Sequoia Capital China and Hillhouse Capital’s GL Ventures. Other existing backers who joined the round include Prosperico Ventures and Med-Fine Capital.
